Arylpyrrolidine derivatives as NK-1 /SSRI antagonists

Details Arylpyrrolidine derivatives as NK-1 /SSRI antagonists Arylpyrrolidine derivatives as NK-1 /SSRI antagonists

2006-11-21

2006-11-21

McKane, Joseph K. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S413000, C514S422000, C548S518000, C548S469000, C548S560000, C548S577000

Reexamination Certificate

active

07138423

ABSTRACT:
The present disclosure relates to chemical compounds and their use in treatment of human diseases. A particular embodiment relates to compounds of Formula (I) or an isomer, a pharmaceutically acceptable salts or solvates thereof or a pharmaceutically acceptable formulation comprising said compoundsare useful for the treatment or prevention of conditions mediated by tachykinins and/or selective inhibition of serotonin reuptake transporter protein. The compounds act as dual NK-1 antagonists and selective serotonin reuptake inhibitors.

REFERENCES:
patent: 6136824 (2000-10-01), MacLeod et al.
patent: WO 2004/005255 (2004-01-01), None
patent: WO 2004/005256 (2004-01-01), None
Kramer et al. (1998), Science, 281, 1640.
Maggi (1995), vol. 26, No. 5, P911 (Abstract).
Kramer, Mark S., et al., “Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors”,Science, 281 (1998) 1640-1645.
Maubach, Karen A., et al., “Novel Strategies for Pharmacotherapy of Depression”,Current Opinion in Chemical Biology, 3 (1999) 481-488.
Rosen, Terry J., et al., “Synthesis and Structure-Activity Relationships of CP-122,721, A Second-Generation NK-1 Receptor Antagonist”, ,Bioorganic&Medicinal Chemistry Letters, 8 (1998) 281-284.
Ryckmans, Thomas, et al., “First Dual NK1Antagonists-Serotonin Reuptake Inhibitors: Synthesis and SAR of a New Class of Potential Antidepressants”,Bioorganic&Medicinal Chemistry Letters, 12 (2002) 261-264.

Affiliated with

Also associated with

Rating

Arylpyrrolidine derivatives as NK-1 /SSRI antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Arylpyrrolidine derivatives as NK-1 /SSRI antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylpyrrolidine derivatives as NK-1 /SSRI antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3696552